Volume 23 - Issue 11 - November 2015
Column
Industry News
11/17/2015
Finacea Foam, 15% is a recently FDA-approved topical treatment for patients experiencing the inflammatory papules and pustules of mild to moderate rosacea.
Finacea Foam, 15% is a recently FDA-approved topical treatment for patients experiencing the inflammatory papules and pustules of mild to moderate rosacea.
Finacea Foam, 15% is a recently...
11/17/2015
The Dermatologist
Spotlight
11/17/2015
Dr. Day is a dermatologist who specializes in laser, cosmetic and medical dermatology in New York City.
Dr. Day is a dermatologist who specializes in laser, cosmetic and medical dermatology in New York City.
Dr. Day is a dermatologist...
11/17/2015
The Dermatologist
Chief Medical Editor Message
11/17/2015
Humans seek direction. Clearly defined and communicated office policies may help patients get their refills and return appointments in more orderly ways. Clear instructions for why, how and when to use medications — which are not given a...
Humans seek direction. Clearly defined and communicated office policies may help patients get their refills and return appointments in more orderly ways. Clear instructions for why, how and when to use medications — which are not given a...
Humans seek direction. Clearly...
11/17/2015
The Dermatologist
Department
Research in Review
11/17/2015
As treatment progresses for epidermolysis bullosa, a need for dermatologists who treat adults with the disorder exists.
As treatment progresses for epidermolysis bullosa, a need for dermatologists who treat adults with the disorder exists.
As treatment progresses for...
11/17/2015
The Dermatologist
Board Review
11/17/2015
1. Difficulty walking and these conjunctival lesions developed during childhood. Which statement is true?
1. Difficulty walking and these conjunctival lesions developed during childhood. Which statement is true?
1. Difficulty walking and...
11/17/2015
The Dermatologist
News
News
11/17/2015
The Fall conference brought together dermatologists to interact, learn and network.
The Fall conference brought together dermatologists to interact, learn and network.
The Fall conference brought...
11/17/2015
The Dermatologist
News
11/17/2015
The FDA approved the Biologics License Application for Imlygic (talimogene laherparepvec, Amgen), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in...
The FDA approved the Biologics License Application for Imlygic (talimogene laherparepvec, Amgen), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in...
The FDA approved the Biologics...
11/17/2015
The Dermatologist
